DLA
ADAP

Douglas Lane & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Douglas Lane & Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,000
Closed -$8.72K – 242
2023
Q4 		$8.72K Hold
11,000
– – ﹤0.01% 245
2023
Q3 		$8.58K Sell
11,000
-2,000
-15% -$1.68K ﹤0.01% 234
2023
Q2 		$12K Hold
13,000
– – ﹤0.01% 233
2023
Q1 		$14.2K Hold
13,000
– – ﹤0.01% 227
2022
Q4 		$19K Buy
+13,000
New +$21.1K ﹤0.01% 226

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Douglas Lane & Associates's ADAP Position: Q1 2024 in Review

Douglas Lane & Associates sold out of Adaptimmune Therapeutics (ADAP) in Q1 2024, closing a stake of 11,000 shares — an estimated $8.72K sold.

Douglas Lane & Associates first reported a position in ADAP in Q4 2022 and held it in 5 quarters. The position peaked at $19K in Q4 2022. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2024.

  • Douglas Lane & Associates reported no remaining Adaptimmune Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Douglas Lane & Associates sold 11,000 Adaptimmune Therapeutics shares in Q1 2024, an estimated $8.72K.
  • Douglas Lane & Associates first reported a position in Adaptimmune Therapeutics in Q4 2022 and held it in 5 quarters.
  • Douglas Lane & Associates's Adaptimmune Therapeutics position peaked at $19K in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2024.

Based on Douglas Lane & Associates's 13F filing for Q1 2024, filed 11 Apr 2024.